Table 1.
| Characteristic | MARINE | ANCHOR | ||||
|---|---|---|---|---|---|---|
| IPE 4 g/day (n = 77) | IPE 2 g/day (n = 76) | Placebo (n = 76) | IPE 4 g/day (n = 233) | IPE 2 g/day (n = 236) | Placebo (n = 233) | |
| Age, years [mean (SD)] | 51.9 (10.27) | 53.4 (9.34) | 53.4 (8.34) | 61.1 (10.03) | 61.8 (9.42) | 61.2 (10.05) |
| Male [n (%)] | 59 (76.6) | 58 (76.3) | 58 (76.3) | 142 (60.9) | 144 (61.0) | 145 (62.2) |
| White [n (%)] | 67 (87.0) | 67 (88.2) | 68 (89.5) | 226 (97.0) | 226 (95.8) | 224 (96.1) |
| Weight, kg [mean (SD)] | 93.2 (18.27) | 92.1 (15.57) | 93.0 (16.92) | 94.5 (18.30) | 95.5 (18.29) | 97.0 (19.14) |
| BMI, kg/m2 [mean (SD)] | 30.4 (4.29) | 30.8 (4.24) | 31.0 (4.25) | 32.7 (4.99) | 32.9 (4.98) | 33.0 (5.04) |
| Diabetes [n (%)] | 22 (28.6) | 20 (26.3) | 21 (27.6) | 171 (73.4) | 172 (72.9) | 171 (73.4) |
| Baseline TG >750 mg/dL [n (%)] | 29 (37.7) | 29 (38.2) | 32 (42.1) | NA | NA | NA |
| Statin use [n (%)]a | ||||||
| Any | 20 (26.0) | 19 (25.0) | 18 (23.7) | 233 (100) | 236 (100) | 233 (100) |
| Atorvastatin | NA | NA | NA | 44 (18.9) | 43 (18.2) | 45 (19.3) |
| Simvastatin | NA | NA | NA | 134 (57.5) | 136 (57.6) | 133 (57.1) |
| Rosuvastatin | NA | NA | NA | 55 (23.6) | 57 (24.2) | 55 (23.6) |
| Statin efficacy regimens [n (%)]b | ||||||
| Lower | NA | NA | NA | 16 (6.9) | 17 (7.2) | 15 (6.4) |
| Medium | NA | NA | NA | 148 (63.5) | 148 (62.7) | 144 (61.8) |
| Higher | NA | NA | NA | 69 (29.6) | 71 (30.1) | 74 (31.8) |
a24.9 % (57/229) of patients in the MARINE study were on statin therapy
bLower-efficacy statin regimens = simvastatin 5–10 mg; medium-efficacy statin regimens = rosuvastatin 5–10 mg, atorvastatin 10–20 mg, simvastatin 20–40 mg, simvastatin 10–20 mg + ezetimibe 5–10 mg; higher-efficacy statin regimens = rosuvastatin 20–40 mg, atorvastatin 40–80 mg, simvastatin 80 mg, simvastatin 40–80 mg + ezetimibe 5–10 mg
BMI body mass index, NA data not applicable to study design, SD standard deviation, TG triglyceride